Cargando…

Correlation between lower extremity arterial disease and skeletal muscle mass in patients with type 2 diabetes mellitus

OBJECTIVES: To evaluate skeletal muscle mass in patients with both type 2 diabetes mellitus (T2DM) and concomitant lower extremity arterial disease (LEAD) and determine the contribution of skeletal muscle mass to macrovascular diseases. METHODS: In total, 112 patients with T2DM were divided into the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yinghui, Ren, Lemeng, Zheng, Fengjie, Zhuang, Xianghua, Jiang, Dongqing, Chen, Shihong, Ni, Yihong, Li, Xiaobao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282344/
https://www.ncbi.nlm.nih.gov/pubmed/32212874
http://dx.doi.org/10.1177/0300060519897483
Descripción
Sumario:OBJECTIVES: To evaluate skeletal muscle mass in patients with both type 2 diabetes mellitus (T2DM) and concomitant lower extremity arterial disease (LEAD) and determine the contribution of skeletal muscle mass to macrovascular diseases. METHODS: In total, 112 patients with T2DM were divided into the T2DM and T2DM + LEAD groups. Hepatic function, renal function, uric acid, blood glucose, and glycated hemoglobin (HbA1C) were measured. Dual-energy X-ray absorptiometry was used to measure visceral fat area and skeletal muscle mass index (SMI). RESULTS: Waist-to-hip ratio, uric acid, and body fat percentage were significantly higher in the T2DM+LEAD group than in the T2DM group; SMI was significantly lower in the T2DM+LEAD group than in the T2DM group. There were no significant differences in albumin, creatinine, fasting blood glucose, HbA1C, or blood lipids. Uric acid, SMI, and body fat percentage were significantly positively correlated with T2DM and concomitant LEAD. Logistic regression analyses suggested that SMI is an independent risk factor for LEAD in T2DM (odds ratio = 1.517; 95% confidence interval: 1.082–2.126). CONCLUSIONS: Skeletal muscle mass is lower in patients with T2DM and concomitant LEAD than in patients with T2DM who do not exhibit LEAD. SMI is an important risk factor for LEAD.